title: Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group.
abstract: BACKGROUND
  Several trials have been performed in the past using glucose, insulin, and potassium infusion (GIK) for the treatment of acute myocardial infarction (AMI). Because of continuing uncertainty about the potential role of this therapeutic intervention, we conducted a randomized trial to evaluate the impact of a GIK solution during the first hours of AMI.
  
  
  RESULTS
  Four hundred seven patients with suspected AMI admitted within 24 hours of symptoms onset were enrolled. In a ratio of 2:1, 268 patients were allocated to receive GIK (high- or low-dose) and 139 to receive control. Phlebitis and serum changes in the plasma concentration of glucose or potassium were observed more often with GIK. A trend toward a nonsignificant reduction in major and minor in-hospital events was observed in patients allocated to GIK. In 252 patients (61.9%) treated with reperfusion strategies, a statistically significant reduction in mortality (relative risk [RR] 0.34; 95% CI: 0.15 to 0.78; 2P=0.008) and a consistent trend toward fewer in-hospital events in the GIK group were observed.
  
  
  CONCLUSIONS
  Our results confirm that a metabolic modulation strategy in the first hours of an AMI is feasible, applicable worldwide, and has mild side effects. The statistically significant mortality reduction in patients who underwent a reperfusion strategy might have important implications for the management of AMI patients. It is now essential to perform a large-scale trial to reliably determine the magnitude of benefit.
authors.affiliation: Department of Cardiology, Instituto Cardiovascular de Rosario, Rosario, Argentina.
authors.forename: R
authors.initials: R
authors.lastname: Díaz
authors.forename: E A
authors.initials: EA
authors.lastname: Paolasso
authors.forename: L S
authors.initials: LS
authors.lastname: Piegas
authors.forename: C D
authors.initials: CD
authors.lastname: Tajer
authors.forename: M G
authors.initials: MG
authors.lastname: Moreno
authors.forename: R
authors.initials: R
authors.lastname: Corvalán
authors.forename: J E
authors.initials: JE
authors.lastname: Isea
authors.forename: G
authors.initials: G
authors.lastname: Romero
mesh_terms: D002314:Cardioplegic Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005947:Glucose / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D010865:Pilot Projects; D011188:Potassium / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D016896:Treatment Outcome
chemical_list: D002314:Cardioplegic Solutions; D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium